Disease/Infection News

RSS

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

Palmetto GBA-TrailBlazer Health cover Renessa treatment of female SUI

Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC -- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia -- have agreed to cover the Renessa(R) treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

24 Sep 2009

Phase III efficacy trial of two AIDS vaccine candidates shows promise

The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial in Thailand. The prime-boost combination appeared to be about 31% effective at preventing infection with HIV.

24 Sep 2009

H1N1 slows growth in US industries and GDP

H1N1 influenza could slow growth in key industries and stall already-weak GDP growth in the third and fourth quarters of 2009, says a health economist in the University of Alabama at Birmingham (UAB) School of Business.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

Obama addresses U.N. General Assembly, calls for 'new era of engagement'

In his first U.N. General Assembly address, President Obama on Wednesday "called for 'a new era of engagement' ... with the world, pledging to work together with other countries while defending the interests of the United States," Reuters reports (9/23).

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

G20 preview: Obama to propose phasing out of fossil fuel subsidies; HIV/AIDS protesters take to streets in Pittsburgh

During the G20 summit opening Thursday in Pittsburgh, President Obama will propose countries around the world phase out government subsidies that promote the production and use of fossil fuels "that spew carbon dioxide, the chief greenhouse gas," the Associated Press reports (Borenstein, 9/23).

24 Sep 2009

Results of Phase III clinical trial of HIV vaccine released

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC(R)( )HIV and AIDSVAX(R) B/E( )lowered the rate of HIV infection by 31.2% compared with placebo.

24 Sep 2009

NIHR to fund patient panel for skin disease research

People who suffer from skin disease are being asked to help make research more effective by joining a new 'Patient Panel'.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

Pregnant women must be vaccinated against H1N1 and seasonal flu

Pregnant women should be sure to get all their flu shots as soon as the vaccines become available this year to protect them against both the seasonal flu and the H1N1 (swine) flu, according to eight leading national maternal and infant health organizations.

24 Sep 2009

Also in global health news: Malawi HIV/AIDS fight; cancer in developing world

Tim Gilbo, the World Bank's director in Malawi, announced on Tuesday that the organization will grant the country $30 million, which will be used to "increase access to prevention, treatment and mitigation services with a focus on behavioural change," SAPA/News24.com reports. Gilbo also said the country should "identify and promote those programmes that are working and drop or redesign those that are not bearing any fruits." UNAIDS Malawi coordinator Desmond Johns said HIV/AIDS is "arguably the single consistent threat in overall development" for Malawi (9/22).

24 Sep 2009

Global effort needed to protect people from species-crossing diseases, Report finds

A team of health experts on Tuesday called for the U.S. "to lead a global effort to protect people from new outbreaks of deadly infectious diseases that originate in animals, such as swine flu, AIDS and SARS," Reuters writes (Morgan, 9/22).

24 Sep 2009

Genetic variation helps identify hepatitis C infected people, according to a study

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

24 Sep 2009

Study of new swine flu vaccines looks for local children to take part

Paediatricians at Bristol Children's Vaccine Centre are looking for 170 children to take part in a study of the two swine 'flu vaccines due to be used in the UK this winter.

23 Sep 2009

Morphotek receives NIAID grant to develop human mAb therapies against staphylococcal-derived pathogens

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to support the development of human monoclonal antibody (mAb) therapies against staphylococcal-derived toxin(s).

23 Sep 2009

Nukepills replenishes its stock of N95 face masks for flu season

Nukepills.com today announced the replenishment of its stock of N95 Particulate Masks just in time for the upcoming flu season. A deluge of online orders in May of this year, in response to media stories of the Swine Flu Virus (H1N1), depleted the company's large inventory in just a few days.

23 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

PSI to double its HIV prevention programs

PSI (Population Services International) announced two significant commitments today at the Clinton Global Initiative (CGI): a doubling of its HIV prevention programs that target at-risk men and, in partnership with Procter & Gamble's Children's Safe Drinking Water program, a commitment that will expand the availability of safe drinking water to vulnerable populations across the globe.

23 Sep 2009